FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA's Fast-Track for Rexulti Raises Concerns

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA rules Otsuka marketing claim overstates Rexulti efficacy

FDA News - SciTechDaily

FDA rushes approval of dementia drug that quadruples risk of death

WD - June/July 2022 by Lawrence Ambrocio - Issuu

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA's accelerated drug approvals often lack confirmatory evidence